Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results

MONTVALE, N.J., May 14 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today reported its financial results for the first quarter ended March 31, 2008.

"We had a productive start to 2008, reporting significant progress with our collaborations and refocusing our operations to advance four high-value programs," said Vaughn M. Kailian, President and Chief Executive Officer. "Roche's recent decision to license R3487/MEM 3454 highlights the potential of the compound, provides a development path forward for our lead nicotinic alpha-7 receptor agonist, strengthens our financial profile and certainly validates our expertise in CNS drug development. We remain on track to achieve the following 2008 goals for each of our four major development programs: completing and announcing top-line results for our Phase 2a trial of R3487/MEM 3454 in cognitive impairment in schizophrenia and our Phase 1 program for R4996/MEM 63908, initiating a Phase 2a trial for MEM 1414, and advancing our 5-HT6 antagonist program into the clinic."

Financial Results

For the quarter ended March 31, 2008, the Company reported a net loss of $13.4 million, or $0.18 per share, compared to a net loss of $8.9 million, or $0.13 per share, for the same period in 2007.

For the quarter ended March 31, 2008, the Company reported revenue of $0.8 million, compared to revenue of $2.7 million for the same period in 2007. The decrease in revenue is a result of the conclusion of the research and development funding portion of the Company's collaboration with Amgen related to the development of PDE10 inhibitors.

Research and development expenses for the quarter ended March 31, 2008 were $11.0 million compared to $9.9 million for the same period in 2007. The change included $3.1 million in increased costs related to the development of R3487/MEM 3454 and R4996/MEM 63908, and a $0.9 million increase related to manufacturing and preclinical costs associated with the 5-HT6 antagonist program, offset by a $3.4 million decrease in costs associated with the clinical development of MEM 1003.

General and administrative expenses for the quarter ended March 31, 2008 were $2.9 million, compared to $2.3 million for the same period in 2007. The change included an increase of $0.2 million in personnel and personnel-related costs, a $0.2 million increase in legal fees, and a $0.2 million increase in outside services.

At March 31, 2008, the Company had cash, cash equivalents and marketable securities of approximately $27.5 million, compared to $38.2 million at the end of 2007. The Company continues to expect that its existing cash, cash equivalents, and marketable securities, together with payments expected to be made under its collaboration agreements, should be sufficient to fund operating expenses, scheduled debt obligations and capital equipment requirements into the first half of 2009.

First Quarter Highlights and Recent Developments

-- Roche Opt-in for R3487/MEM 3454. In May, Roche exercised its option to

license R3487/MEM 3454, Memory Pharmaceuticals' lead nicotinic alpha-7

receptor agonist, for further development and commercialization in

psychiatric and neurological disorders. The option exercise triggers a

$6.0 million milestone payment and entitles Memory Pharmaceuticals to

future payments upon the achievement of additional milestones and

royalties on product sales, including a $17.0 million milestone payment

upon the completion of the ongoing Phase 2a study in cognitive

impairment associated with schizophrenia. In addition, Memory

Pharmaceuticals retains an option to co-promote R3487/MEM 3454 in the

United States.

-- Expanded Development Program for R3487/MEM 3454 in Schizophrenia. In

February, Memory Pharmaceuticals announced that it plans to conduct a

clinical study of R3487/MEM 3454 on two biomarkers of schizophrenia,

P50 sensory gating and mismatch negativity, in patients with

schizophrenia. External costs of the biomarker study, and additional

formulation and manufacturing activities for R3487/MEM 3454, will be

funded by Roche. The Company expects to begin the study this summer,

with data available by early 2009.

-- Expanded PDE10 Collaboration with Amgen. In March, the Company

extended the preclinical research portion of its collaboration with

Amgen focused on the development of PDE10 inhibitors for certain

neurological and psychiatric disorders. Memory Pharmaceuticals agreed

to commit and fund certain preclinical research resources and provide

increased access to its screening technologies to the collaboration for

an additional twelve months. In exchange, Memory Pharmaceuticals will

receive increased milestone payments upon the achievement of certain

predefined development events for the program. The parties also

expanded the scope of compounds eligible for higher tier royalties

under the agreement.

-- Refocused Operations. In March, Memory Pharmaceuticals realigned its

operations and reallocated its resources to refocus its near-term and

mid-term efforts on four major development and clinical programs. The

Company reduced its workforce and research discovery efforts and

shifted its resources toward development activities with two partnered

programs, its nicotinic alpha-7 receptor agonist collaboration with

Roche and the PDE10 collaboration with Amgen, and two proprietary

programs, its PDE4 inhibitor and 5-HT6 antagonist programs. The

Company expects the savings from these initiatives to be in the range

of $2-3 million on an annualized basis.

-- Receipt of Nasdaq Notification. On April 2, 2008, the Company received

written notification from Nasdaq that, as of December 31, 2007, the

Company was not in compliance with the minimum $10.0 million

stockholders' equity requirement for continued listing under

Marketplace Rule 4450(a)(3). As required by Nasdaq, the Company has

submitted a plan to achieve and sustain compliance with all of The

Nasdaq Global Market listing requirements and the time frame required

to complete that plan.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on May 14, 2008, at 9:00 a.m. EDT to discuss the Company's first quarter 2008 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' collaborations; Memory Pharmaceuticals' dependence on preclinical and clinical investigators, preclinical and clinical research organizations, manufacturers and consultants; protecting the intellectual property developed by or licensed to Memory Pharmaceuticals; and Memory Pharmaceuticals ability to maintain listing on the Nasdaq Global Market. These and other risks are described in greater detail in Memory Pharmaceuticals' filings with the Securities and Exchange Commission. Memory Pharmaceuticals may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Memory Pharmaceuticals disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.



(in thousands - except per share information)


Three Three

Months Months

Ended Ended

March 31, March 31,

2008 2007

Revenue $752 $2,690

Operating expenses:

Research and development 10,982 9,851

General and administrative 2,874 2,253

Total operating expenses 13,856 12,104

Loss from operations (13,104) (9,414)

Other income 24 -

Interest income (expense), net (365) 551

Loss before income taxes (13,445) (8,863)

Income tax expense - -

Net loss $(13,445) $(8,863)

Basic and diluted net loss

per share of common stock $(0.18) $(0.13)

Basic and diluted weighted average number

of shares of common stock outstanding 72,726 70,146



(in thousands)


March 31, December 31,

2008 2007


Cash, cash equivalents and marketable securities $27,493 $38,201

Other current assets 1,359 1,417

Restricted cash 505 505

Deferred financing costs, net 444 519

Property and equipment, net 5,525 5,868

Total assets $35,326 $46,510


Current liabilities (excluding deferred revenue) $11,674 $8,789

Equipment notes payable, less current portion 31 66

Loan payable, less current portion 9,669 10,831

Deferred revenue 17,715 18,051

Other non-current liabilities 495 506

Total liabilities 39,584 38,243

Stockholders' (deficit) equity (4,258) 8,267

Total liabilities and

stockholders' (deficit) equity $35,326 $46,510

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
(Date:10/12/2015)... SAN FRANCISCO , October 12, 2015 ... reach USD 6.49 billion by 2022, according to a new ... can be attributed to rise in incidence of oncology diseases ... detection market is expected to reach USD 6.49 billion ... Research, Inc. This growth in demand can be attributed to ...
(Date:10/12/2015)... 12, 2015  Patara Pharma, a clinical-stage biotechnology ... diseases and conditions, today announced the closing of ... Concurrent with the close of its sale of ... and Security Agreement with Silicon Valley Bank whereby ... Patara will use the funds from the financing ...
(Date:10/12/2015)... Belgium , Oct. 12, 2015 VolitionRx ... from a completed clinical study of its NuQ ® ... in the online issue of Clinical Epigenetics , the ... was conducted in collaboration with Lund ... Roland Andersson , MD, PhD, Professor of Surgery and Vice-Dean, ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... LifeTrak ... the launch of LifeTrak Zoom, the world’s first amphibious fitness tracker that seeks to ... offers flexwear technology and accurate heart rate monitoring both in water and ...
Breaking Biology Technology:
(Date:9/29/2015)... , Sept. 29, 2015 ... employee productivity while also saving energy , Minimized ... as Low Power Active Mode and embedded Fujitsu PalmSecure ... Fujitsu today shows that good things ... and refreshed models to its enterprise desktop and mobile ...
(Date:9/28/2015)... YORK , Sept. 28, 2015 /PRNewswire/ ... announced today that its expedited traveler service ... innovative platform transforms travel, bringing a frictionless ... its members. "CLEAR offers our ... enhances customer service," said Jim Smith ...
(Date:9/28/2015)... SAN FRANCISCO , September 28, 2015 ... size is expected to reach USD 12.03 billion by ... to 2020. Technological advancements such as Backside Illumination (BSI) ... revenue growth over the forecast period.      ... the back of the chip to reduce loss and, ...
Breaking Biology News(10 mins):